Unlock instant, AI-driven research and patent intelligence for your innovation.

Preparation method of esculene mesylate impurity

A technology for methanesulfonic acid and impurities, which is applied in the field of synthesis of pharmaceutical impurities, can solve problems such as affecting the quality of pharmaceuticals, and achieve the effects of simple post-processing and mild reaction conditions.

Active Publication Date: 2022-03-22
苏州正济药业有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The starting materials, intermediates, reaction by-products, and degradation impurities in the synthesis process of eribulin mesylate may all become impurities remaining in the final product (eribulin mesylate), thereby affecting the quality of the drug
At present, there are few reports on the research on related substances of eribulin mesylate and the preparation of impurities

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of esculene mesylate impurity
  • Preparation method of esculene mesylate impurity
  • Preparation method of esculene mesylate impurity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021]

[0022] Add 1.0 g of compound I-A to the reaction flask, then add 20 g of dichloromethane, 0.5 g of 2,4,6-collidine, and 0.01 g of pyridine. Then, 0.21 g of benzoyl chloride was added dropwise at an internal temperature of 0°C. After reacting for 0.5 hour, 20 g of water and 20 g of dichloromethane were added, and the layers were separated. The organic layer was spin-dried to obtain I-B-1.

[0023]

[0024] Add 1.14g of compound I-B-1 to the reaction flask, then add 22.8g of dichloromethane, 0.86g of pyridine, and 0.95g of methanesulfonic anhydride, then magnetically stir at room temperature, react for 0.5 hours, add 30g of water, and separate layers. The aqueous phase was back-extracted with 21 g of dichloromethane, and the combined organic phases were concentrated under reduced pressure to obtain 1.25 g of compound I-C-1.

[0025]

[0026] Add 1.25g compound I-C-1 to the reaction flask, then add 63ml DMF, 0.27gNaN 3 , 0.01 g pyridine. Then control the int...

Embodiment 2

[0033]

[0034] Add 1.0 g of compound I-A to the reaction flask, then add 20 g of dichloromethane, 0.5 g of 2,4,6-collidine, and 0.01 g of pyridine. Then, 0.12 g of acetyl chloride was added dropwise at an internal temperature of 0°C. After reacting for 0.5 hour, 20 g of water and 20 g of dichloromethane were added, and the layers were separated. The organic layer was spin-dried to obtain I-B-2.

[0035]

[0036] Add 1.04g of compound I-B-2 to the reaction flask, then add 22.8g of dichloromethane, 0.86g of pyridine, and 0.95g of methanesulfonic anhydride, then magnetically stir at room temperature, and react for 0.5 hours. Add 30g of water and separate layers. The aqueous phase was back-extracted with 21 g of dichloromethane, and the combined organic phases were concentrated under reduced pressure to obtain 1.13 g of compound I-C-2.

[0037]

[0038] Add 1.13g compound I-C-2 to the reaction flask, then add 63ml DMF, 0.27gNaN 3 , 0.01 g pyridine. Then control the i...

Embodiment 3

[0044]

[0045]Add 1.0 g of compound I-A to the reaction flask, then add 20 g of dichloromethane, 0.5 g of 2,4,6-collidine, and 0.01 g of pyridine. Then, 0.21 g of benzoyl chloride was added dropwise at an internal temperature of 0°C. After reacting for 0.5 hour, 20 g of water and 20 g of dichloromethane were added, and the layers were separated. The organic layer was spin-dried to obtain I-B-1.

[0046]

[0047] Add 1.13g of compound I-B-1 to the reaction flask, then add 22.8g of dichloromethane, 0.86g of pyridine, and 1.77g of p-toluenesulfonic anhydride, then magnetically stir at room temperature and react for 0.5 hours. Add 30g of water and separate layers. The aqueous phase was back-extracted with 21 g of dichloromethane, and the combined organic phases were concentrated under reduced pressure to obtain 1.35 g of compound I-C-3.

[0048]

[0049] Add 1.35g compound I-C-3 to the reaction flask, then add 63ml DMF, 0.27gNaN 3 , 0.01 g pyridine. Then control the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method of an esculene mesylate impurity, and belongs to the field of synthesis of medicine impurities. The preparation method provided by the invention is mild in reaction condition and simple in post-treatment, and can be used for preparing a compound with the purity meeting the requirement on a large scale, and the compound is used as an impurity reference substance for quality research on the esculene mesylate.

Description

technical field [0001] The invention relates to the synthesis of pharmaceutical impurities, in particular to a method for preparing eribulin mesylate related substances. Background technique [0002] Eribulin is a structurally optimized derivative of halichondrin B, a macrolide compound extracted from the marine natural product Halichondria okadai, and is a halichondrin-like microtubule dynamics inhibitor. Since the FDA first approved Eribulin Mesylate (Halaven) Injection on November 15, 2010 for the treatment of patients with metastatic breast cancer who have received at least two chemotherapy regimens, Eisai has actively expanded the use of Eribulin Mesylate new indications. On January 28, 2016, the FDA approved it for the second-line treatment of unresectable or metastatic liposarcoma, becoming the world's first new anticancer drug that can significantly prolong the survival of patients with advanced soft tissue sarcoma. At present, the drug has been approved for the tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D493/22
CPCC07D493/22Y02P20/55
Inventor 王怀秋邹晓东谭健罗林
Owner 苏州正济药业有限公司